First, we addressed the question if the inhibited tumor cell proliferation observed after KRAS-esiRNA-treatment of human CRC xenografts ([35] and Fig 2) is also the cause for decreased tumor growth in cetuximab-antibody-coupled PIK3CA-esiRNA (C-PIK3CA-esiRNA) treatment. Here, KRAS is linked to colorectal carcinoma.